Literature DB >> 3076395

From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists.

G J Sanger1, F D King.   

Abstract

Metoclopramide is a stimulant of upper gut motility and an anti-emetic. The mechanisms by which the drug exerts these actions has been the subject of considerable research, which is briefly reviewed in this article. From the viewpoint of drug discovery, the properties of metoclopramide have directly led to the development of selective gut motility stimulants and 5-HT3 receptor antagonists. These events and the potential clinical use of such compounds are reviewed in detail.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3076395

Source DB:  PubMed          Journal:  Drug Des Deliv        ISSN: 0884-2884


  10 in total

Review 1.  Neuropharmacology of emesis in relation to clinical response.

Authors:  B Costall; R J Naylor
Journal:  Br J Cancer Suppl       Date:  1992-12

Review 2.  The role of medicinal chemistry in drug research.

Authors:  W Soudijn
Journal:  Pharm Weekbl Sci       Date:  1991-08-23

3.  5-HT4 receptor mediated facilitation of the emptying phase of the peristaltic reflex in the guinea-pig isolated ileum.

Authors:  B Costall; R J Naylor; B R Tuladhar
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

4.  Validation of a column-switching high-performance liquid chromatographic (HPLC) method for determination of ML-1035 and its five metabolites in plasma.

Authors:  B S Kuo; J C Poole; K K Hwang
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

Review 5.  Ondansetron. Therapeutic use as an antiemetic.

Authors:  R J Milne; R C Heel
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

6.  5-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae.

Authors:  G S Baxter; D A Craig; D E Clarke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

7.  Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.

Authors:  Nicholas L Meyers; Roger I Hickling
Journal:  Drugs R D       Date:  2008

8.  A Comparison of 5-HT3 Receptor Antagonist and Metoclopramide in the Patients Receiving Chemotherapeutic Regimens Including CMF, CAF and CHOP.

Authors:  Kazem Anvari; Mehdi Seilanian-Toussi; Hossein Hosseinzad-Ashkiki; Soodabeh Shahidsales
Journal:  Iran J Cancer Prev       Date:  2015 Mar-Apr

Review 9.  A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.

Authors:  Gareth J Sanger; Paul L R Andrews
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

Review 10.  The involvement of TRPV1 in emesis and anti-emesis.

Authors:  John A Rudd; Eugene Nalivaiko; Norio Matsuki; Christina Wan; Paul Lr Andrews
Journal:  Temperature (Austin)       Date:  2015-05-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.